AIMC Topic: Cyclin-Dependent Kinase 4

Clear Filters Showing 1 to 7 of 7 articles

Efficacy and safety of first-line CDK4/6 inhibitors plus AI therapy for patients with HR +/HER2- advanced breast cancer: a network meta-analysis.

BMC cancer May 8, 2025
BACKGROUND: CDK4/6 inhibitors plus aromatase inhibitors (AI) significantly improve the therapeutic effect of initial treatment for HR + /HER2- advanced breast cancer. However, there is a lack of head-to-head randomized controlled trials involving the...
Aminopyridines Antineoplastic Combined Chemotherapy Protocols Treatment Outcome Randomized Controlled Trials as Topic Female Breast Neoplasms Protein Kinase Inhibitors Benzimidazoles Humans Receptors, Estrogen Progression-Free Survival Cyclin-Dependent Kinase 4 Receptor, ErbB-2 Cyclin-Dependent Kinase 6 Aromatase Inhibitors Network Meta-Analysis as Topic Purines Receptors, Progesterone
View on PubMed DOI

Using prognostic signatures and machine learning to identify core features associated with response to CDK4/6 inhibitor-based therapy in metastatic breast cancer.

Oncogene Feb 26, 2025
CDK4/6 inhibitors in combination with endocrine therapy are widely used to treat HR+/HER2- metastatic breast cancer leading to improved progression-free survival (PFS) compared to single agent endocrine therapy. Over 300 patients receiving standard-o...
Machine Learning Prognosis Female Humans Progression-Free Survival Neoplasm Metastasis Protein Kinase Inhibitors Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Breast Neoplasms Middle Aged Gene Expression Regulation, Neoplastic Aged Adult
View on PubMed DOI

Using bioinformatics and artificial intelligence to map the cyclin-dependent kinase 4/6 inhibitor biomarker landscape in breast cancer.

Future oncology (London, England) Nov 12, 2024
A cyclin-dependent kinase 4/6 (CDK4/6) inhibitor combined with endocrine therapy is the standard-of-care for patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative advanced breast cancer. However, not all patients r...
Computational Biology Drug Resistance, Neoplasm Protein Kinase Inhibitors Female Breast Neoplasms Biomarkers, Tumor Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Humans Artificial Intelligence
View on PubMed DOI

A deep learning model of tumor cell architecture elucidates response and resistance to CDK4/6 inhibitors.

Nature cancer Mar 5, 2024
Cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6is) have revolutionized breast cancer therapy. However, <50% of patients have an objective response, and nearly all patients develop resistance during therapy. To elucidate the underlying mechanisms, ...
Humans Female Protein Kinase Inhibitors Piperazines Breast Neoplasms Cyclin-Dependent Kinase 4 Cell Line, Tumor Xenograft Model Antitumor Assays Animals Cyclin-Dependent Kinase 6 Drug Resistance, Neoplasm Mice Deep Learning Pyridines
View on PubMed DOI

Drug-Drug interactions and special considerations in breast cancer patients treated with CDK4/6 inhibitors: A comprehensive review.

Cancer treatment reviews Jun 1, 2025
Cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) have reshaped the treatment paradigm of hormone receptor positive (HR + )/HER2-negative breast cancer in both adjuvant and metastatic settings. However, their metabolism via the cytochrome P450 (CYP3A4...
Pyridines Piperazines Drug Interactions Female Breast Neoplasms Antineoplastic Agents Cyclin-Dependent Kinase 4 Humans Cyclin-Dependent Kinase 6 Protein Kinase Inhibitors Aminopyridines Benzimidazoles Purines
View on PubMed DOI

How Artificial Intelligence Unravels the Complex Web of Cancer Drug Response.

Cancer research Jun 4, 2024
The intersection of precision medicine and artificial intelligence (AI) holds profound implications for cancer treatment, with the potential to significantly advance our understanding of drug responses based on the intricate architecture of tumor cel...
Drug Resistance, Neoplasm Protein Kinase Inhibitors Cyclin-Dependent Kinase 4 Cyclin-Dependent Kinase 6 Neoplasms Antineoplastic Agents Deep Learning Female Breast Neoplasms Humans Artificial Intelligence Precision Medicine
View on PubMed DOI

Effect of Fanbaicao (Herba Potentillae Discoloris) oil on the expression of p21 and CDK4 in HepG2 cells.

Journal of traditional Chinese medicine = Chung i tsa chih ying wen pan Aug 1, 2016
OBJECTIVE: To research the anti-cancer mechanism of the Traditional Chinese Medicine Fanbaicao (Herba Potentillae Discoloris) oil in the human hepatoma cell line HepG2.
Apoptosis Cell Proliferation Cyclin-Dependent Kinase 4 Humans Hep G2 Cells Potentilla Drugs, Chinese Herbal Liver Neoplasms Cyclin-Dependent Kinase Inhibitor p21 Cell Cycle
View on PubMed DOI
Popular Topics
Recent Journals